Browsing by Author "Simic, Radoje (16744648200)"
Now showing 1 - 13 of 13
- Results Per Page
- Sort Options
- Some of the metrics are blocked by yourconsent settings
Publication A Correlation Study of the Colorectal Cancer Statistics and Economic Indicators in Selected Balkan Countries(2020) ;Vekic, Berislav (8253989200) ;Dragojevic-Simic, Viktorija (59157732500) ;Jakovljevic, Mihajlo (14318929700) ;Kalezic, Marko (57190377163) ;Zagorac, Zagor (59162669900) ;Dragovic, Sasa (56811009700) ;Zivic, Rastko (6701921833) ;Pilipovic, Filip (57194021948) ;Simic, Radoje (16744648200) ;Jovanovic, Dejan (57215410633) ;Milovanovic, Jovana (57215418875)Rancic, Nemanja (54941042300)Colorectal cancer (CRC) is one of the most commonly diagnosed malignant neoplasms. The aim of the study was to evaluate and correlate most important epidemiological and economic indicators of CRC in 11 selected Balkan countries. The number of new CRC cases was 56,960, and the highest 5-year CRC prevalence was in Slovenia, Croatia, and Greece. Age-standardized CRC incidence rates were highest in Slovenia, Serbia, and Croatia, and age-standardized mortality rates were highest in Croatia, Serbia, and Bulgaria. Current Health Expenditure as % of Gross Domestic Product was the highest in Bosnia and Herzegovina and Serbia. The GDP per capita levels have shown positive correlation with the CRC incidence rate and prevalence. Absolute numbers of new and death-related CRC cases and 5-year prevalence in absolute numbers have shown strong positive correlation with GDP in million current US$. It has been shown that various economic indicators can be linked to the rate of incidence and prevalence of the CRC patients in the selected Balkan countries. Therefore, economic factors can influence the epidemiology of CRC, and heavy CRC burden in the Balkan region may be one of the indexes of the economic development. © Copyright © 2020 Vekic, Dragojevic-Simic, Jakovljevic, Kalezic, Zagorac, Dragovic, Zivic, Pilipovic, Simic, Jovanovic, Milovanovic and Rancic. - Some of the metrics are blocked by yourconsent settings
Publication An overview of antiviral strategies for coronavirus 2 (SARS-CoV-2) infection with special reference to antimalarial drugs chloroquine and hydroxychloroquine(2021) ;Dragojevic Simic, Viktorija (59157732500) ;Miljkovic, Milijana (56694268200) ;Stamenkovic, Dusica (23037217500) ;Vekic, Berislav (8253989200) ;Ratkovic, Nenad (6506233469) ;Simic, Radoje (16744648200)Rancic, Nemanja (54941042300)At present, neither specific antiviral drugs, nor vaccine is recommended for coronavirus disease 2019 (COVID-19) treatment. In this review we discuss the drugs suggested as therapy for COVID-19 infection, with a focus on chloroquine and hydroxychloroquine. The list of drugs used for COVID-19 treatment includes a combination of lopinavir and ritonavir, remdesivir, favipiravir, alpha-interferon, ribavirin, atazanavir, umifenovir, and tocilizumab. As their efficacy and safety are under investigation, none of the regulatory agencies approved them for the treatment of COVID-19 infection. Although chloroquine and hydroxychloroquine possess antiviral and immunomodulatory effects, in practice benefit of their use for COVID-19 treatment is controversial. Several studies investigating hydroxychloroquine were stopped and the French national medicines regulator suspended its use in clinical trials because of safety concerns. The results from the double-blind, randomised clinical trials, including large number of participants, will add better insight into the role of these two drugs as already available and affordable, antimalarial therapy. The ethical issue on emergency use of chloroquine and hydroxychloroquine in the settings of COVID-19 should be carefully managed, with adherence to the “monitored emergency use of unregistered and experimental interventions” (MEURI) framework or be ethically approved as a trial, as stated by the WHO. Potential shortage of chloroquine/hydroxychloroquine on the market can be overbridged with regular prescriptions by medical doctors and national drug agency should ensure sufficient quantities of these drugs for standard indications. © 2020 John Wiley & Sons Ltd - Some of the metrics are blocked by yourconsent settings
Publication Cost Analysis of Health Examination Screening Program for Ischemic Heart Disease in Active-Duty Military Personnel in the Middle-Income Country(2021) ;Simic, Radoje (16744648200) ;Ratkovic, Nenad (6506233469) ;Dragojevic Simic, Viktorija (59157732500) ;Savkovic, Zorica (56122760700) ;Jakovljevic, Mihajlo (14318929700) ;Peric, Vitomir (57222487217) ;Pandrc, Milena (57190422802)Rancic, Nemanja (54941042300)Cardiovascular diseases, including ischemic heart disease, are the most common causes of morbidity and death in the world, including Serbia, as a middle-income European country. The aim of the study was to determine the costs of preventive examinations for ischemic heart disease in active-duty military personnel, as well as to assess whether this was justified from the point of view of the limited health resources allocated for the treatment of the Republic of Serbia population. This is a retrospective cost-preventive study which included 738 male active-duty military personnel, aged from 23 to 58. The costs of primary prevention of ischemic heart disease in this population were investigated. Out of 738 subjects examined, arterial hypertension was detected in 101 subjects (in 74 of them, arterial hypertension was registered for the first time, while 27 subjects were already subjected to pharmacotherapy for arterial hypertension). Average costs of all services during the periodic-health-examination screening program were €76.96 per subject. However, average costs of all services during the periodic-health-examination screening program for patients with newfound arterial hypertension and poorly regulated arterial hypertension were €767.54 per patient and €2,103.63 per patient, respectively. Since periodic-health-examination screening program in military personnel enabled not only discovery of patient with newfound arterial hypertension but also regular monitoring of those who are already on antihypertensive therapy, significant savings of €690.58 per patient and €2,026.67 per patient can be achieved, respectively. As financial resources for providing health care in Serbia, as a middle-income country, are limited, further efforts should be put on screening programs for ischemic heart disease due to possible significant savings. © Copyright © 2021 Simic, Ratkovic, Dragojevic Simic, Savkovic, Jakovljevic, Peric, Pandrc and Rancic. - Some of the metrics are blocked by yourconsent settings
Publication Latissimus dorsi free flap phalloplasty: a systematic review(2020) ;Kojovic, Vladimir (23970795300) ;Marjanovic, Marko (57219904208) ;Radenkovic, Ana (57218323344) ;Ilic, Predrag (57207790079) ;Simic, Radoje (16744648200)Bojovic, Branko (36670846000)A phalloplasty is a complex genital reconstruction procedure of creating a neophallus. Several techniques to create a neophallus are described, based on different vascularized flaps, and each of them has its advantages and drawbacks. The aim of this study is to present musculocutaneous latissimus dorsi (MLD) flap as a viable option for total phalloplasty, with an interest in clinical outcomes and complications. A comprehensive literature review of all available reports about MLD flap phalloplasty was made. The following keywords were used on PubMed: latissimus dorsi musculocutaneous/myocutaneous free flap and phalloplasty. Research criteria revealed five articles and the results of 182 patients were analyzed. A total number of the patients, indications, operative technique, follow-up period, postoperative results, and complications were presented. In conclusion, MLD free flap presents a good choice for phalloplasty providing sufficient amount of tissue for safe implantation of penile prosthesis and successful penetrative sexual intercourse. The erogenous sensitivity is preserved with clitoris or glans penis incorporated into the base of the neophallus, and voiding in a standing position is achievable after urethral reconstruction. The main drawback is the lack of tactile sensation of the neophallus and the significant advantage is a well-concealed donor site. © 2020, The Author(s), under exclusive licence to Springer Nature Limited part of Springer Nature. - Some of the metrics are blocked by yourconsent settings
Publication Medical cost of breast cancer services in Serbia between 2010 and 2019: national data report(2024) ;Rancic, Nemanja (54941042300) ;Todorovic, Milos (58982216600) ;Stepovic, Milos (57204973515) ;Vekic, Stefan (57219232360) ;Kostic, Dejan (8619696100) ;Ratkovic, Milena (58982037200) ;Radevic, Svetlana (55102896900) ;Simic, Radoje (16744648200)Dragojevic Simic, Viktorija (59157732500)[No abstract available] - Some of the metrics are blocked by yourconsent settings
Publication Medical cost of colorectal cancer services in serbia between 2014 and 2017: National data report(2019) ;Vekic, Berislav (8253989200) ;Dragojevic-Simic, Viktorija (59157732500) ;Jakovljevic, Mihajlo (14318929700) ;Pilipovic, Filip (57194021948) ;Simic, Radoje (16744648200) ;Zivic, Rastko (6701921833) ;Radovanovic, Dragce (57213489763)Rancic, Nemanja (54941042300)[No abstract available] - Some of the metrics are blocked by yourconsent settings
Publication Medical cost of colorectal cancer services in serbia between 2014 and 2017: National data report(2019) ;Vekic, Berislav (8253989200) ;Dragojevic-Simic, Viktorija (59157732500) ;Jakovljevic, Mihajlo (14318929700) ;Pilipovic, Filip (57194021948) ;Simic, Radoje (16744648200) ;Zivic, Rastko (6701921833) ;Radovanovic, Dragce (57213489763)Rancic, Nemanja (54941042300)[No abstract available] - Some of the metrics are blocked by yourconsent settings
Publication Metamizole Utilization and Expenditure During 6-Year Period: Serbia vs. Croatia(2018) ;Miljkovic, Milijana (56694268200) ;Dragojevic-Simic, Viktorija (59157732500) ;Rancic, Nemanja (54941042300) ;Simic, Radoje (16744648200) ;Pekez-Pavlisko, Tanja (56784359000) ;Kovacevic, Aleksandra (55546820300)Stamenkovic, Dusica (23037217500)Background: Metamizole is a medication with analgesic, antipyretic, spasmolytic, and weak anti-inflammatory effects. The aim of our study was to evaluate a six-year trend in the utilization and expenditure of metamizole in comparison to other group of licensed non-opioid analgesics in Serbia and Croatia, in order to rationalize its use and prescribing in these countries. Methods: The data of metamizole vs. all other non-opioid analgesics utilization and expenditure in Serbia and Croatia was analyzed according to the WHO methodology and expressed as defined daily doses per 1,000 inhabitants per day (DDD/1,000 inhabitants/per day) and total costs, respectively, during the 6-year period from 2010 to 2015. Results: In the observed period, utilization of metamizole was 3.31 fold higher in Serbia than in Croatia (median in Serbia was 2.238 vs. 0.675 in Croatia DDD/1,000 inhabitants/per day/per year). Expenditure of metamizole in the same period was 5.29-fold higher in Serbia than in Croatia (median in Serbia was 1,738,192.51 €/per year vs. 328,355.03 €/per year in Croatia). Conclusion: Utilization and expenditure of non-opioid analgesics, including metamizole, in Serbia was significantly higher comparing with Croatia.Further research is needed to determine whether the current analgesic consumption in Serbia meets the needs of the patient. The benefits of metamizole should be weighed against the risk of metamizole-induced adverse effects. Until then, its prescribing should be based on indications and the appropriate duration of therapy. © Copyright © 2018 Miljkovic, Dragojevic-Simic, Rancic, Simic, Pekez-Pavlisko, Kovacevic and Stamenkovic. - Some of the metrics are blocked by yourconsent settings
Publication Recent Experience: Corticosteroids as a First-line Therapy in Children with Multisystem Inflammatory Syndrome and COVID-19-related Myocardial Damage(2021) ;Vukomanovic, Vladislav (55881072000) ;Krasic, Stasa (57192096021) ;Prijic, Sergej (20734985500) ;Ninic, Sanja (51864038300) ;Popovic, Sasa (57200324005) ;Petrovic, Gordana (57211071996) ;Ristic, Snezana (57213555181) ;Simic, Radoje (16744648200) ;Cerovic, Ivana (57220213990)Nesic, Dejan (26023585700)Background: Cardiovascular complications with myocarditis in multisystem inflammatory syndrome in children (MIS-C) associated with severe acute respiratory syndrome coronavirus 2 infection have been reported, but the optimal therapeutic strategy remains unknown. Methods: A retrospective cohort study included 19 patients with acute left ventricular systolic dysfunction associated with MIS-C, average years of age 13.2 ± 3.8, treated from April 2020 to April 2021. Results: Treatment failure (TF) was observed in 8 patients (in the intravenous immunoglobulin [IVIG] group 7/10; in the corticosteroid [CS] group 1/9). The independent risk factor for TF was IVIG treatment (odds ratio [OR] 18.6, 95% confidence interval [CI] 1.6-222.93, P = 0.02). Patients initially treated with CS became afebrile during in-hospital day 1 (1.5, interquartile range [IQR] 1-2), while IVIG-treated patients became afebrile on in-hospital day 4 (IQR 2-4.25), after CS was added. The C-reactive protein (CRP) significantly declined in CS-treated patients on day 2 (P = 0.01), while in the IVIG group, CRP decreased significantly on the fourth day (P = 0.04). Sodium and albumin levels were higher on third in-hospital day in the CS group than in the IVIG group (P = 0.015, P = 0.03). A significant improvement and normalization of ejection fraction (EF) during the first 3 days was observed only in the CS group (P = 0.005). ICU stays were shorter in the CS group (4, IQR 2-5.5) than in the IVIG group (IVIG group 7, IQR 6-8.5) (P = 0.002). Conclusions: Among children with MIS-C with cardiovascular involvement, treatment with CS was associated with faster normalization of LV EF, fever, laboratory analysis, and shorter ICU than IVIG-treated patients. © 2021 Lippincott Williams and Wilkins. All rights reserved. - Some of the metrics are blocked by yourconsent settings
Publication The last 3 decade of vaccination coverage in the Balkan and Eastern Europe countries with reference to the impact of the COVID-19 pandemic(2024) ;Stepovic, Milos (57204973515) ;Dragojevic Simic, Viktorija (59157732500) ;Zivanovic Macuzic, Ivana (23570133700) ;Simic, Radoje (16744648200) ;Vekic, Stefan (57219232360) ;Sekulic, Marija (57188576722) ;Radovanovic, Snezana (36053830900) ;Maricic, Milena (57210826188) ;Sorak, Marija (16403488100) ;Suljagic, Vesna (6506075339) ;Vojinovic, Radisa (11640450400)Rancic, Nemanja (54941042300)[No abstract available] - Some of the metrics are blocked by yourconsent settings
Publication The last 3 decade of vaccination coverage in the Balkan and Eastern Europe countries with reference to the impact of the COVID-19 pandemic(2024) ;Stepovic, Milos (57204973515) ;Dragojevic Simic, Viktorija (59157732500) ;Zivanovic Macuzic, Ivana (23570133700) ;Simic, Radoje (16744648200) ;Vekic, Stefan (57219232360) ;Sekulic, Marija (57188576722) ;Radovanovic, Snezana (36053830900) ;Maricic, Milena (57210826188) ;Sorak, Marija (16403488100) ;Suljagic, Vesna (6506075339) ;Vojinovic, Radisa (11640450400)Rancic, Nemanja (54941042300)[No abstract available] - Some of the metrics are blocked by yourconsent settings
Publication Utilization of Parenteral Morphine by Application of ATC/DDD Methodology: Retrospective Study in the Referral Teaching Hospital(2017) ;Dragojevic-Simic, Viktorija (59157732500) ;Rancic, Nemanja (54941042300) ;Stamenkovic, Dusica (23037217500)Simic, Radoje (16744648200)Background: Few studies analyzed the pattern of opioid analgesic utilization in hospital settings. The aim of this study was to determine the consumption pattern of parenteral morphine in patients hospitalized in the Serbian referral teaching hospital and to correlate it with utilization at the national and international level. Methods: In retrospective study, the required data were extracted from medical records of surgical patients who received parenteral morphine in the 5-year period, from 2011 to 2015. We used the Anatomical Therapeutic Chemical Classification/Defined Daily Doses (DDD) international system for consumption evaluation. Results: While the number of performed surgical procedures in our hospital steadily increased from 2011 to 2015, the number of inpatient bed-days decreased from 2012. However, the consumption of parenteral morphine varied and was not more than 0.867 DDD/100 bed-days in the observed period. Conclusion: Based on the available data, parenteral morphine consumption in our hospital was lower compared with international data. The low level of morphine use in the hospital was in accordance with national data, and compared with other countries, morphine consumption applied for medical indications in Serbia was low. Adequate legal provision to ensure the availability of opioids, better education and training of medical personnel, as well as multidisciplinary approach should enable more rational and individual pain management in the future, not only within the hospitals. © Copyright © 2017 Dragojevic-Simic, Rancic, Stamenkovic and Simic. - Some of the metrics are blocked by yourconsent settings
Publication Very Rare Mediastinal Location of Kaposiform Haemangioendothelioma: a Case Report and a Brief Review of the Previously Published Cases(2020) ;Djuricic, Slavisa M. (6603108728) ;Sarajlija, Adrijan (26027638400) ;Djokic, Dragomir (56017672300)Simic, Radoje (16744648200)Kaposiform haemangioendothelioma (KHE) is a rare, locally invasive vascular tumour that is commonly associated with the Kasabach-Merritt phenomenon (KMP). A case of a five-month-old female infant admitted for dyspnoea, stridor, and skin haematoma is presented. Computerised tomography of the chest showed a tumour mass occupying mediastinum and most of the left hemithorax, while laboratory analysis revealed a thrombocytopaenia and a consumption coagulop-athy. Histology of tumour biopsy was characteristic of KHE with a component of tufted angioma. Corticosteroid treatment initially induced a reduction in tumour size, but progression occurred four weeks later and led to a fatal outcome despite additional chemotherapy. After a literature search, we found only 18 cases of me-diastinal KHE published so far, with 21 % fatality rate. In the present case several risk factors for adverse outcome were present: onset of disease in early infancy, a large volume of the tumour, mediastinal location, KMP, and partial response to available therapy. © 2020 Djuricic et al.
